CABA

Cabaletta Bio, Inc.

3.45 USD

Last updated Sep 4, 20:35 UTC

Yesterday HIGH

$3.75

Yesterday LOW

$3.47

52w HIGH

$4.23

52w LOW

$1.42

EPS

-0.34

PE

-10.15

Next Earnings

Nov 9, 2026

Overview News Unusual Options Flow Government Trades Fundamentals

Cabaletta Bio, Inc. stock is up 27.31% since 30 days ago. The next earnings date is Nov 9, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 6 September’s closed higher than August. In the last 6 Unusual Options Trades, there were 3 PUTs, 3 CALLs. 50% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

28 Jul 19:59	15 Jan, 2027	4.50	PUT	119	51
12 Aug 13:30	19 Feb, 2027	2.50	PUT	300	10
25 Aug 14:08	16 Oct, 2026	5.00	PUT	129	14
27 Aug 18:02	21 Jan, 2028	0.50	CALL	151	304
03 Sep 16:36	18 Sep, 2026	3.00	CALL	2250	4031
03 Sep 19:56	18 Sep, 2026	2.50	CALL	300	7611

Advanced Data Unlock

Benzinga Newsdesk

Thu May 14, 2026

Cabaletta Bio Q1 EPS $(0.39), Inline

Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.39) per share which met the analyst consensus estimate. This is a 45.07 percent increase over losses of $(0.71) per share from the same period last year.
Benzinga Insights

Mon May 4, 2026

12 Health Care Stocks Moving In Monday's Intraday Session
Avi Kapoor

Mon May 4, 2026

Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big Stocks Moving Higher On Monday

Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday after reporting better-than-expected financial results. Other top gainers included companies like Cabaletta Bio Inc, Celcuity Inc, and Xerox Holdings Corp.
Benzinga Newsdesk

Mon May 4, 2026

Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $30 Price Target

Cantor Fitzgerald analyst Josh Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $30 price target.
Benzinga Newsdesk

Mon May 4, 2026

Cabaletta Bio shares are trading higher. The company announced the pricing of its $150 million offering of 51.73 million shares at $2.90 per share.
Benzinga Newsdesk

Mon May 4, 2026

Cabaletta Prices Share Sale Of 51.73M Shares at $2.90 to Fund Autoimmune Therapy Development

Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with
Benzinga Newsdesk

Tue Apr 28, 2026

Cabaletta Bio Announces Commercial Agreement With Cellares To Supply Rese-Cel Using Cellares' Automated Cell Shuttle To Enable Flexible Low-Cost Commercial Scaling
Benzinga Newsdesk

Mon Apr 27, 2026

Cabaletta Bio Reveals Multiple Upcoming Presentations, Including Data on Rese-Cel without Preconditioning and Rese-Cel with Automated Manufacturing, At The ASGCT 2026 Annual Meeting
Benzinga Newsdesk

Tue Apr 14, 2026

Cabaletta Bio Doses First Two Patients Rese-cel Manufactured on Cellares' Automated Cell Shuttle Platform

First two GMP doses of rese-cel manufactured on the Cell Shuttle™ met all release specifications, were delivered on time, and have been infused into patients within Cabaletta Bio's RESET™ clinical trial
Avi Kapoor

Fri Apr 10, 2026

FGI Industries, Nouveau Monde Graphite And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Dow futures down 0.1%. FGI Industries (NASDAQ: FGI) reported mixed results for Q4, with losses of 29 cents per share beating estimates but sales missing. Stock down 7.8% in pre-market. Other stocks moving lower in pre-market: BBGI, MFI, JTAI, RMIX, TMCR, NMG, SHMD, ANL, CABA, FUFU.

HC Wainwright & Co.

Tue Sep 1, 19:14

buy

confirm
Wells Fargo

Fri Aug 14, 16:44

hold

confirm